GB CellBio™ technology is a platform for capturing CTC using patented iFiltration™ solution in automated systems (a2000 and FX10).
Both CellBio™ a2000 and FX10 offers automated solution in your laboratory. CellBio™ a2000 offers compact solution where FX10 offers higher capacity up to 10 samples per run.
Starting from a simple blood draw, which is non-invasive and can be repeated as often as needed, the system enriches to provide intact cancer cells, providing a real-time sample for subsequent analyses by common laboratory techniques, enabling a complete picture of the cancer. Unlike ctDNA, which is limited to DNA analysis and is the focus for most of the liquid biopsy industry, a full range of analyses can be undertaken with CTCs, giving a potential alternative to a tissue biopsy.
GB CellBio™ is an automated platform that capture and harvest circulating tumor and other abnormal cells from blood for clinical and research applications.

The CellBio system offers several advantages including high specificity, sensitivity, and cancer capture rate from 7.5-mL blood samples, delivering results within 90 minutes. The system is applicable to cancer screening, diagnosis, monitoring, and prognosis; it offers optimal treatment and enhances patients' quality of life. During the non-invasive sampling process, the number of CTCs in the blood can be fully monitored, and the system's capture rate of over 90% of cancer cells surpasses the industry standard. The CellBio FX10 accommodates 10 samples simultaneously and features a full-color touch screen, while the CellBio a2000 can handle two samples at a time in compact labs. With over 8,000 samples already processed, GBC has demonstrated strong efficacy.